Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator
暂无分享,去创建一个
K. Swedberg | J. Cleland | A. Maggioni | P. Carson | W. Levy | I. Anand | K. Patton | J. Poole | R. Rho | R. Shadman
[1] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[2] S. Solomon,et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. , 2011, Journal of the American College of Cardiology.
[3] John L Sapp,et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.
[4] A. Natale,et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. , 2010, Heart rhythm.
[5] James A. Ker,et al. Heart failure : review , 2010 .
[6] H. Ghanbari,et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.
[7] D. Mozaffarian,et al. Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.
[8] A. Laupacis,et al. Design and implementation of a population-based registry of Implantable Cardioverter Defibrillators (ICDs) in Ontario. , 2008, Heart rhythm.
[9] J. Ornato,et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.
[10] Mark A Hlatky,et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. , 2008, Heart rhythm.
[11] L. Lund,et al. Abstract 2308: Does Peak Oxygen Consumption add to the Seattle Heart Failure Model? , 2007 .
[12] D. Mozaffarian,et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. , 2007, The American journal of cardiology.
[13] D. Mozaffarian,et al. Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.
[14] M. Haigney,et al. Gender Differences in Na/Ca Exchanger Current and β‐Adrenergic Responsiveness in Heart Failure in Pig Myocytes , 2007, Annals of the New York Academy of Sciences.
[15] C. White,et al. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death , 2006, Journal of internal medicine.
[16] D. Mozaffarian,et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.
[17] S. Connolly,et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. , 2005, European heart journal.
[18] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[19] L. Tavazzi,et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. , 2005, Journal of cardiac failure.
[20] T. Saikawa,et al. Gender Differences in Autonomic Modulation of Ventricular Repolarization in Humans , 2005, Journal of cardiovascular electrophysiology.
[21] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[22] J. Spertus,et al. Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. , 2004, The American journal of cardiology.
[23] Hugh Calkins,et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.
[24] W. Kannel,et al. Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.
[25] A. Kadish,et al. DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.
[26] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[27] N. Hollenberg,et al. Literature alert , 2002 .
[28] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[29] G. Helguera,et al. Remodeling of Kv4.3 Potassium Channel Gene Expression under the Control of Sex Hormones* , 2001, The Journal of Biological Chemistry.
[30] Andrew N. Carr,et al. Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium. , 2001, Journal of molecular and cellular cardiology.
[31] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[32] C M O'Connor,et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.